74 results about "Galactosamine" patented technology

The invention relates to the technical field of pharmaceutical preparations, and discloses a composition with liver protection and antioxidation effects and a preparation method thereof.The composition is prepared from galactosamine modified astragalus membranaceus exosome, schisandra chinensis nanocrystals, liquorice-chitosan nanoparticles, lactobacillus acidophilus freeze-dried powder, beta-(1, 3) / (1, 3, 4-tetramethyl-1, 3-pentanediol monoisobutyrate) sourced from saccharomyces cerevisiae, and beta-(1, 3, 4-tetramethyl-1, 3-pentanediol monoisobutyrate). And (6) a dextran, grape exosome-curcumin hybrid vesicle freeze-dried powder, a curcumin-mitochondrial targeting peptide compound, a resveratrol-hydroxypropyl-beta-cyclodextrin inclusion compound and reduced panthenol. According to the liver-protecting and anti-oxidation composition disclosed by the invention, multi-dimensional intervention on liver protection is realized through an elaborately designed ternary system. The system is composed of a traditional Chinese medicine extract, a microorganism-plant exosome combination and a high-bioavailability antioxidant, all the parts have a synergistic effect, and the liver protection effect is remarkably improved.

The invention relates to the technical field of aquaculture, in particular to a leiocassis longirostris intestinal health functional additive based on spermaceti soxhlet metabolite. The Leiocassis longirostris intestinal health functional additive comprises the following functional components: chondroitin sulfate, N-acetyl-D-galactosamine, 4 ', 4', 4 ', 4', 4 ', 4', 4 ', 4', 4 ', 4', 4 ', 4'- The composition is prepared from the following raw materials: 4, 6-dihydroxyflavone, polydatin, ascorbic acid, glucoside, arabinogalactan, 3-O-beta-D-galactopyranosyl-L-arabinose, tyramine, 4A-hydroxytetrahydrobiopterin, hyaluronic acid and 3-mercapto-2-butanol. According to the technical scheme, the technical problem that an existing probiotic viable bacterium preparation is difficult to meet the intestinal health management requirement in intensive culture of the leiocassis longirostris can be solved. Compared with the prior art, the scheme is more efficient, stable and safe, healthy development of the Leiocassis longirostris breeding industry can be effectively promoted, and the method has ideal application and popularization prospects.

The disclosure provides methods for synthesis of peracetylgalactosamine-1-pentanoic acid, also called peracetylated D-galactosamine C5 linker or GalNAc C5 linker, using a vegetal source as a starting material, such as vegetal-sourced D-glucosamine or D-glucosamine hydrochloride. Also provided are methods for purifying the peracetylgalactosamine-1-pentanoic acid, or GalNAc C5 linker, thus produced so that the end product comprises fewer impurities.

The invention discloses an analysis method for determining the content of galactosamine in sulfated polysaccharide based on high-temperature hydrochloric acid hydrolysis and an ion chromatograph method, which comprises the following steps: hydrolyzing a test sample with hydrochloric acid at high temperature to release galactosamine, separating with an ion chromatograph and a sugar analysis column, detecting with a pulsed ampere detector, and determining the content of galactosamine in sulfated polysaccharide according to a galactosamine reference substance. And quantitatively analyzing the content of galactosamine in the test sample. The method disclosed by the invention has the advantages of simplicity, rapidness, accuracy, high efficiency, no need of derivation treatment and the like.

The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents such as small interfering RNA (siRNA) molecules, able to inhibit proprotein convertase subtilisin kexin 9 (PCSK9) gene expression. Also disclosed are pharmaceutical compositions that include PCSK9 RNAi agents and methods of use thereof. The PCSK9 RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that comprise N-acetyl-galactosamine, to facilitate the delivery to hepatocyte cells. Delivery of the PCSK9 RNAi agents in vivo provides for in vivo provides for inhibition of PCSK9 gene expression and thereby reduction of PCSK9 protein. The RNAi agents can be used in methods of treatment of diseases or disorders mediated at least in part by PCSK9 gene expression, including among others hypercholesterolemia, familial hypercholesterolemia including heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH), familial hypobetalipoproteinemia, hyperlipidemia, coronary artery disease, polygenic dyslipidemia, heart disease, cardiovascular disease (CVD) including clinical atherosclerotic cardiovascular disease (ASCVD).

The invention discloses raspberry leaf polysaccharide as well as a preparation method and application thereof. The average relative molecular weight of the raspberry leaf polysaccharide is 44755 Da, and the raspberry leaf polysaccharide is mainly prepared from mannose, glucose, rhamnose, glucosamine, galactosamine, glucuronic acid, galactose, xylose and arabinose according to the molar ratio of (3.138): (0.894): (12.349): (4.590): (26.498): (18.681): (22.842): (2.690): (8.317). Besides, methylation and nuclear magnetic resonance analysis show that the raspberry leaf polysaccharide is complex polysaccharide, and it can be reasonably deduced that the raspberry leaf polysaccharide is mainly composed of a large number of HG structural domain-like structures and a part of RG-I structures with side chains. Meanwhile, the raspberry leaf polysaccharide disclosed by the invention can be used for inhibiting the injury of kidney tissues and reducing the generation of kidney inflammatory factors.

The invention relates to the technical field of culture media, and particularly discloses a candida chromogenic culture medium as well as a preparation method and application thereof. The candida chromogenic culture medium disclosed by the invention is prepared from the following components in concentration: 10 to 11 g / L of peptone, 12 to 17 g / L of agar, 7 to 9 g / L of glucose, 1 to 2 g / L of chromogenic substrate and 0.4 to 0.6 g / L of bacteriostatic agent, the chromogenic substrate is formed by mixing heavy 4-nitrophenyl-N-acetyl-beta-D-galactosamine and 4-methylumbelliferone-beta-D-N-acetyl galactosamine, and the chromogenic substrate is formed by mixing heavy 4-nitrophenyl-N-acetyl-beta-D- The bacteriostatic agent is prepared by mixing chloramphenicol, taurocholic acid and nalidixic acid. When being used for detecting and identifying candida albicans, candida tropicalis, candida krusei and candida glabrata, the chromogenic culture medium provided by the invention has strong specificity, short identification time and wide practical application value.

The application discloses a preparation method of a liver-targeting drug delivery carrier, and comprises the following steps: synthesizing bromic acid N-acetylgalactosamine ester; and synthesizing the liver-targeting drug delivery carrier. x The liver-targeting drug delivery carrier GalNAc-C x CD is designed based on bromic acid N-acetylgalactosamine ester Br-C GalNAc and beta-cyclodextrin, which can include poorly soluble drugs to be delivered to the liver and released in a targeted manner, greatly improves the targeting efficiency on the liver, and the targeting delivery rate can reach more than 70%, while effectively improving the solubility and bioavailability of the poorly soluble drugs, improving the drug treatment effect, providing a new strategy for the delivery of other poorly soluble drugs for treating liver diseases, and laying a foundation for the development of drugs and functional foods for intervening NASH.

The present disclosure provides a combination comprising an antibody that specifically binds to C5 and a C5 iRNA, which is a glycoconjugate containing a ligand with a terminal N-acetylgalactosamine (GalNAc) residue and / or N-acetylglucosamine (GlcNAc) residue. A method for reducing degradation of glycoconjugate RNA by the beta-hexosaminidase enzyme is also provided. The present disclosure also includes a method for treating or preventing a C5-related disease or disorder by administering one or more doses of an anti-C5 antibody or antigen-binding fragment thereof in combination with one or more doses of a C5 iRNA; preferably, the anti-C5 antibody or fragment and the C5 iRNA are in a combination. The present disclosure also includes a dosing regimen for treating a C5-related disease or disorder with a combination of an anti-C5 antibody and a C5 iRNA in either a treatment-naive subject or a subject switching from a previous C5 inhibitor therapy.

The present invention discloses a Sepia esculenta ink polysaccharide for improving high-glucose damage of endothelial cells, and a preparation method and application thereof. The Sepia esculenta ink polysaccharide has a polysaccharide backbone composed of fucose, galactosamine, mannose, and N-acetylglucosamine, and has a glucuronic acid branch chain at the C-3 position of mannose. It is an aminopolysaccharide with a weight-average molecular weight of 10-16 kDa and a sulfation degree of 8%-15%. Through experimental verification, compared with similar compounds, the Sepia esculenta ink polysaccharide can effectively improve the state of endothelial cells and maintain the normal filtration function of vascular endothelium. At the same time, the risk of bleeding side effects of the Sepia esculenta ink polysaccharide is significantly lower than that of similar polysaccharides, and it has higher safety in use. Furthermore, the Sepia esculenta ink polysaccharide can be used to develop adjuvant therapeutic drugs for late-stage diabetic lesions, filling the gap in such products on the current market.

The current invention concerns methods for the synthesis of 6-azido-6-deoxy-2-N-acetyl-monosaccharide-nucleoside diphosphate, in particular 6-azido-6-deoxy-2-N-acetyl-D-galactosamine-nucleoside diphosphate or 6-azido-6-deoxy-2-N-acetyl-D-glucosamine-nucleoside diphosphate. The synthesis method according to the invention is characterized by being highly efficient and high yielding. Also part of the present invention are key intermediates of this process.

This disclosure relates to RNAi agents capable of inhibiting complement factor B (CFB) gene expression. Pharmaceutical compositions containing CFB RNAi agents and methods of use thereof are also disclosed. The CFB RNAi agents disclosed herein may be conjugated to a targeted ligand containing an N-acetyl-galactosamine ligand to facilitate in vivo delivery to hepatocytes. RNAi agents can be used in methods of treating diseases, disorders, or conditions partially mediated by CFB gene expression, including IgA nephropathy (IgAN), C3 glomerulopathy (C3G), immune complex-mediated membrane proliferative glomerulonephritis (IC-MPGN), lupus nephritis (LN), anti-glomerular basement membrane antibody disease (anti-GBM), ischemia-reperfusion injury and T-cell-mediated rejection in kidney transplantation (TCMR), anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, age-related macular degeneration (AMD) including early and / or intermediate-stage AMD, geographic atrophy (GA), glaucoma, Doyne honeycomb retinal dystrophy, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), pre-eclampsia, rheumatoid arthritis (RA), and / or other complement-mediated disorders.

The present disclosure relates to RNAi agents, e.g., double-stranded RNAi agents, capable of inhibiting the expression of a mitochondrial amidoxime reducing component 1 (MARC1) gene. Also disclosed are pharmaceutical compositions comprising the MARC1 RNAi agent and methods of using the same. In some embodiments, the MARC1 RNAi agents disclosed herein can be conjugated to targeting ligands, including ligands comprising N-acetyl-galactosamine, to facilitate delivery to hepatocytes. Delivery of the MARC1 RNAi agent in vivo provides inhibition of MARC1 gene expression. RNAi agents may be used in methods of treating diseases, disorders or conditions mediated in part by MARC1 gene expression, including non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), alcoholic fatty liver disease, autoimmune hepatitis, hepatic fibrosis, cirrhosis, elevated blood cholesterol levels, hypertriglyceridemia, liver disease, and / or other MARC1 related diseases.

The application belongs to the technical field of biological medicine, and particularly relates to a galactosamine-doxetaxel conjugate as well as a preparation method and application thereof. First, doxetaxel and 3,3'-diseleno-dipropionic acid are used as raw materials, and after heating reaction, 3,3'-diseleno-dipropionic acid doxetaxel is obtained. Then, the obtained 3,3'-diseleno-dipropionic acid doxetaxel and galactosamine are used as raw materials, and after heating reaction, galactosamine-3,3'-diseleno-dipropionic acid doxetaxel conjugate is obtained through column chromatography separation and purification. The obtained conjugate can be specifically recognized by endogenous lectin receptors (such as asialoglycoprotein receptor ASGPR) which are highly expressed on the surface of hepatoma cells, so as to be taken up by hepatoma cells through a receptor-mediated pathway, and has application prospect in the direction of hepatoma targeted treatment.

The invention discloses lake sphingosine bacteria AT4-200, exopolysaccharides thereof and application of the lake sphingosine bacteria AT4-200 in promoting plant growth and improving plant stress resistance, relates to the technical field of microbial technology and biostimulant application, and discloses the lake sphingosine bacteria AT4-200 separated and purified from tobacco rhizosphere and the exopolysaccharides generated by the lake sphingosine bacteria AT4-200, the molecular weight of the exopolysaccharides is about 1340Da, and the exopolysaccharides can be applied to plant growth promotion and plant stress resistance improvement. The polysaccharide mainly comprises five monosaccharides, namely mannose, glucose, glucosamine, galactosamine and rhamnose. Application verifies that the strain and / or exopolysaccharide thereof can significantly increase agronomic characters such as leaf area and dry weight of tobacco, can effectively improve salt tolerance of soybean under salt stress, and can be used as a novel, low-cost and efficient plant biostimulant or stress-resistant preparation.

The present disclosure relates to RNAi agents able to inhibit Complement Factor B (CFB) gene expression. Also disclosed are pharmaceutical compositions that include CFB RNAi agents and methods of use thereof. The CFB RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that comprise N-acetyl-galactosamine, to facilitate the in vivo delivery to hepatocyte cells. The RNAi agents can be used in methods of treatment of diseases, disorders, or symptoms mediated in part by CFB gene expression, including IgA nephropathy (IgAN), C3 glomerulopathy (C3G), immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN), lupus nephritis (LN), Anti-Glomerular Basement Membrane disease (anti-GBM), ischemia reperfusion injury and T-cell mediated rejection (TCMR) in kidney transplantation, anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, age-related macular degeneration (AMD), including early and / or intermediate AMD, geographic atrophy (GA), glaucoma, Doyne honeycomb retinal dystrophy, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), pre-eclampsia, rheumatoid arthritis (RA), and / or other complement-mediated diseases.

The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, able to inhibit Yellow Fever Virus (YFV) viral genome expression. Also disclosed are pharmaceutical compositions that include YFV RNAi agents and methods of use thereof. The YFV RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that comprise N-acetyl-galactosamine, to facilitate the delivery to hepatocyte cells. Delivery of the YFV RNAi agents in vivo provides for inhibition of YFV viral genome expression. The RNAi agents can be used in methods of treatment of diseases, disorders, or symptoms caused by YFV infection, such as liver failure.

We provide a technology that can activate NRF2. [Solution] An NRF2 activator comprising one or more chondroitin sulfate oligosaccharides selected from (a) to (c) below as an active ingredient: (a) a disaccharide having a chondroitin sulfate structure (a disaccharide of CS), (b) a trisaccharide having two N-acetyl-D-galactosamine residues and a chondroitin sulfate structure (a trisaccharide of CS having two GalNac residues), (c) a tetrasaccharide having a chondroitin sulfate structure (a tetrasaccharide of CS). According to the present invention, NRF2 can be activated. This is expected to promote homeostatic reactions in the body, such as antioxidant reactions, anti-inflammatory reactions, and detoxification reactions, and contribute to maintaining and improving health. It is also expected to contribute to the prevention and improvement of various unhealthy conditions and diseases caused by oxidative stress, inflammation, and toxic chemicals.

Disclosed is a method for preparing an N-acetyl-D-galactosamine tripolymer precursor. In the preparation of the tripolymer precursor, a compound 4 is prepared by the following steps: adding a compound 3, a 4 Å molecular sieve powder, and a reaction solvent into a reactor; inflating and changing protective gas for 3 times; stirring; firstly adding an enol, followed by slowly dropping trimethylsilyl trifluoromethanesulfonate; after a reaction, quenching the reaction with an alkali solution; and performing extraction, separating liquid, washing, drying, filtration, etc., so as to obtain the compound 4. According to the present disclosure, the problems of various production processes, more times of column chromatography for purification of products accompanied by lower yields in the prior art are solved.

The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, capable of inhibiting Apolipoprotein C-III (also called APOC3, apoC-III, APOC-III, and APO C-III) gene expression, and compositions that include APOC3 RNAi agents. The APOC3 RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that include N-acetyl-galactosamine, to facilitate the delivery to cells, including to hepatocytes. Pharmaceutical compositions that include one or more APOC3 RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the APOC3 RNAi agents in vivo provides for inhibition of APOC3 gene expression, and can result in lower triglycerides and / or cholesterol levels in the subject. The APOC3 RNAi agents can be used in methods of treatment of APOC3-related diseases and disorders, including hypertriglyceridemia, cardiovascular disease, and other metabolic-related disorders and diseases.

The present disclosure includes methods of treating 05-associated disease or disorder, such as myasthenia gravis, with a combination that includes an antibody or antigen-binding fragment thereof that binds specifically to C5 and a C5 iRNA which is a glycoconjugate that includes a ligand having terminal N-Acetylgalactosamine (GalNAc) residues and / or N-acetylglucosamine (GIcNAc) residues; or with the C5 iRNA monotherapy.

The present disclosure includes methods of treating C5-associated disease or disorder, such as myasthenia gravis, with a combination that includes an antibody or antigen-binding fragment thereof that binds specifically to C5 and a C5 iRNA which is a glycoconjugate that includes a ligand having terminal N-Acetylgalactosamine (GalNAc) residues and / or N-acetylglucosamine (GlcNAc) residues; or with the C5 iRNA monotherapy.

The present application provides methods of functionalizing an organ or tissue of a mammal by administering a nutrient (e.g., peracetylated N-azido galactosamine Ac4GalNAz) to the mammal or by culturing an organ or tissue in a bioreactor containing such nutrient. The present application also provides methods of selectively functionalizing extracellular matrix (ECM) of an organ or tissue of a mammal by administering a nutrient (e.g., peracetylated N-azido galactosamine Ac4GalNAz) to the mammal. In some aspects, the present application provides a decellularized scaffold of a mammalian organ or tissue comprising an extracellular matrix, wherein the extracellular matrix of the decellularized scaffold is functionalized with a chemical group that is reactive in a bioorthogonal chemical reaction, such as an azide chemical group. The present application also provides biological prosthetic mesh and mammalian organs and tissues for transplantation prepared according to the methods of the application.

The invention discloses an oxygen / nitrogen-rich organic molecule functionalized graphene oxide composite material as well as preparation and application thereof, and relates to the field of nano composite materials. The composite material comprises a substrate and oxygen / nitrogen-rich organic molecules which are connected through a grafting reaction. The preparation method comprises the following steps: S1, uniformly dispersing graphene oxide in anhydrous N, N-dimethylformamide (DMF) to obtain a graphene oxide dispersion liquid; and S2, uniformly mixing the obtained graphene oxide dispersion liquid with D-galactosamine hydrochloride, and carrying out amidation reaction under a catalytic condition to obtain the oxygen / nitrogen-rich organic molecule functionalized graphene oxide composite material. The composite material can be used as an adsorbent for adsorbing phenolic pollutants, shows excellent adsorption selectivity to 1-naphthol, can efficiently enrich and separate low-concentration 1-naphthol, has good reusability, and has wide application prospects in the adsorption separation process of wastewater treatment.

The present invention relates to a method for the synthesis of 6-azido-6-deoxy-2-N-acetyl-monosaccharide-nucleotide diphosphates, in particular 6-azido-6-deoxy-2-N-acetyl-D-galactosamine-nucleotide diphosphate or 6-azido-6-deoxy-2-N-acetyl-D-glucosamine-nucleotide diphosphate. The synthesis method according to the present invention is characterized by high efficiency and high yield. Another part of the present invention is a key intermediate of the method.

The invention relates to a novel process for generating N-acetylgalactosamine (GalNAc) clusters using a nitrilase and conjugating said GalNAc clusters to oligonucleotides, such as oligonucleotides for use in therapy. In particular, the nitrilase is used to catalyse the conversion of a trinitrile intermediate to a triacid intermediate.

The invention relates to uridine diphosphate-N-difluoroacetyl galactosamine as well as a preparation method and application thereof. The chemical structure of the UDP-GalNDFA is similar to that of a natural substrate UDP-GalNAc, and the core difference is that N-acetyl at the site 2 of the UDP-GalNDFA is replaced by N-difluoroacetyl. The preparation method comprises the following steps: (1) preparing difluoroacetyl galactosamine; and (2) preparing the UDP-GalNDFA by taking the difluoroacetyl galactosamine as a substrate. As a novel artificial donor sugar, the UDP-GalNDFA has the characteristics of high activity, difficulty in hydrolysis and capability of being artificially synthesized. Compared with the existing donor sugar UDP-GalNTFA, the glucose UDP-GalNTFA has higher catalytic activity on glycosyl transferase, has stronger stability, is not easy to hydrolyze, and can be used as a donor substrate for synthesizing a chondroitin oligosaccharide skeleton, a chondroitin oligosaccharide intermediate and a chondroitin oligosaccharide derivative by a chemical enzyme method.

The invention discloses a method for detecting a soil microbial marker-amino sugar by direct ion chromatography, and relates to the technical field of biomarker analysis, and the method comprises the following steps: adding a soil sample into a 6mol / L hydrochloric acid solution, and hydrolyzing at 105 DEG C for 8 hours; drying the hydrolysate with nitrogen, redissolving with ultrapure water, centrifuging, taking supernate, and filtering with a 0.22 mu m filter membrane to obtain a to-be-detected solution; the method comprises the following steps: injecting a to-be-detected solution into an ion chromatography system provided with an electrochemical detector, and carrying out gradient elution by adopting an anion exchange chromatographic column and taking a mixed solution of sodium hydroxide and sodium acetate as a mobile phase to realize separation and quantitative detection of glucosamine (GlcN), galactosamine (GalN), aminomannose (ManN) and muramic acid (Mur). A highly toxic derivatization step necessary for a traditional method is omitted, a sample can be directly injected through three-step purification after acid hydrolysis, and efficient separation of four amino sugars is realized by matching with a special ion chromatography system.

Described herein is a beta-glycoside of structural formula (I) wherein X1 or X2 is-C (= O) OR, R is an alkyl group comprising from 1 to 6 (1 to 4) carbon atoms, and Y is a monovalent sugar selected from the group consisting of beta-D-glucose, beta-D-galactose, beta-D-glucuronic acid, N-acetylglucosamine or galactosamine, where when X1 is-C (= O) OR then X2 is-H, and when X2 is-C (= O) OR then X1 is-H. Such beta-glycosides can be used as indicators, such as biological indicators. (I)

The present application relates to compounds of N-acetylgalactosamine (GalNAc) origin and oligonucleotides. Provided herein are compounds of N-acetylgalactosamine (GalNAc) origin, modified oligonucleotides, and methods of modulating protein function and treating diseases, disorders, and symptoms in a subject.